β-Adrenergic Receptor Signaling Affects Tumor Microenvironment

This article originally appeared here.
Share this content:
β-Adrenergic Receptor Signaling Affects Tumor Microenvironment
β-Adrenergic Receptor Signaling Affects Tumor Microenvironment

WEDNESDAY, Sept. 13, 2017 (HealthDay News) -- β2-adrenergic receptor (β-AR) signaling in host immune cells regulates CD8+ T-cell frequency and functional orientation within the tumor microenvironment, according to a study published online Aug. 17 in Cancer Research.

Mark J. Bucsek, from Roswell Park Cancer Institute in Buffalo, N.Y., and colleagues used physiologic, pharmacologic, and genetic strategies to reduce adrenergic stress signaling in two preclinical mouse tumor models.

The researchers found that reducing β-AR signaling facilitated conversion of tumors to an immunologically active tumor microenvironment. In addition to an elevated effector CD8+ T-cell to CD4+ regulatory T-cell ratio, there was increased intra-tumoral frequency of CD8+ T-cells with an effector phenotype and decreased expression of PD-1. The conversion significantly increased the efficacy of anti-PD-1-chekpoint blockade.

"These data highlight the potential of adrenergic stress and norepinephrine-driven β-adrenergic receptor signaling to regulate the immune status of the tumor microenvironment and supports the strategic use of clinically available β-blockers in patients to improve responses to immunotherapy," the authors write.

Abstract
Full Text

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Global Prevalence of Insufficient Activity 27.5 Percent

Global Prevalence of Insufficient Activity 27.5 Percent

Levels of insufficient physical activity stable between 2001, 2016; increase seen in high-income countries

HTN Tx Intensification Common Upon Discharge in U.S. Vets

HTN Tx Intensification Common Upon Discharge in U.S. ...

Fourteen percent of older adults admitted to hospital for non-cardiac conditions had intensification of tx

Quarterly Canakinumab Reduces Risk for Gout Attacks

Quarterly Canakinumab Reduces Risk for Gout Attacks

Doesn't affect serum uric acid levels over time, but targets interleukin-1β

is free, fast, and customized just for you!




Already a member?

Sign In Now »